Children with sickle cell disease (SCD) and stroke receive chronic transfusions to prevent stroke recurrence. Transfusion risks including infection, erythrocyte allosensitization, and iron overload suggest a need for alternative therapies. We previously used hydroxyurea (HU) and phlebotomy in two young adults with SCD and stroke as an alternative to transfusions. We have now prospectively discontinued transfusions in 16 pediatric patients with SCD and stroke. Reasons to discontinue transfusions included erythrocyte alloantibodies or autoantibodies, recurrent stroke on transfusions, iron overload, noncompliance, and deferoxamine allergy. HU was started at 15 mg/kg/d and escalated to 30 mg/kg/d based on hematologic toxicity. Patients with iron overload underwent phlebotomy. The children have been off transfusions 22 months, (range, 3 to 52 months). Their average HU dose is 24.9 ± 4.2 mg/kg/d, hemoglobin concentration is 9.4 ± 1.3 g/dL, and mean corpuscular volume (MCV) is 112 ± 9 fL. Maximum percentage fetal hemoglobin (%HbF) is 20.6% ± 8.0% and percentage HbF-containing erythrocytes (%F cells) is 79.3% ± 14.7%. Fourteen patients underwent phlebotomy with an average of 8,993 mL (267 mL/kg) removed. Serum ferritin has decreased from 2,630 to 424 ng/mL, and 4 children have normal ferritin values. Three patients (19%) had neurological events considered recurrent stroke, each 3 to 4 months after discontinuing transfusions, but before maximal HU effects. These preliminary data suggest some children with SCD and stroke may discontinue chronic transfusions and use HU therapy to prevent stroke recurrence. Phlebotomy is well-tolerated and significantly reduces iron overload. Modifications in HU therapy to raise HbF more rapidly might increase protection against stroke recurrence.

STROKE IS one of the most devastating clinical complications that occurs in children with sickle cell disease (SCD) and is an important cause of death in this patient population.1-3 Approximately 5% to 10% of children with SCD will develop a stroke, most often in the first decade of life.4,5 The pathological event is usually infarctive and results from stenosis or occlusion of the large vessels, especially the internal carotid and proximal cerebral arteries.6,7 Despite prompt aggressive medical intervention, including complete blood exchange, many children with SCD and stroke have residual physical and neuropsychological deficits.8-10 

Several studies have documented a high rate of stroke recurrence in children with SCD who receive no specific preventive therapy. A report from the Jamaican pediatric cohort described stroke recurrence in 6 of 13 children (46%), with a median interval to recurrence of 9 months after the first stroke.4 Powars et al11reported a recurrence rate of 67% in 15 long-term survivors of stroke, with a temporal clustering of additional neurological events in the first 24 to 36 months after the initial stroke. Russell et al12 reported stroke recurrence in 9 of 10 (90%) of untransfused pediatric patients with SCD and stroke.

Because of this high risk of stroke recurrence, affected children are typically treated with monthly erythrocyte transfusions designed to reduce the concentration of sickled erythrocytes.13,14 A chronic transfusion regimen is at least 80% to 90% successful in preventing stroke recurrence,12,15-18 although the optimal duration of transfusions is not known. A 70% stroke recurrence rate was observed after the prospective discontinuation of a short-term (1- to 2-year) transfusion regimen,19 and a 50% recurrence rate was observed after prospective discontinuation of a long-term (5- to 12-year) transfusion regimen.20 Most pediatric hematologists, therefore, recommend indefinite chronic transfusions to prevent recurrent stroke, despite the long-term risks of transfusions, including the possible transmission of infectious agents, erythrocyte allosensitization, and iron overload.

We recently reported two young adults with SCD and stroke who were unable to continue chronic transfusion therapy; transfusions were discontinued, and the patients were treated with oral hydroxyurea (HU) as prophylaxis against stroke recurrence.21 A phlebotomy program was used to reduce iron overload and stimulate endogenous erythropoiesis. Both patients responded to the HU therapy with elevated levels of fetal hemoglobin (HbF) and HbF-containing erythrocytes (F cells) and had no stroke recurrence during nearly 3 years of HU therapy. In addition, each patient tolerated phlebotomy well and had diminution in serum ferritin values, suggesting a reduction in total body iron stores. Based on this anecdotal success, we prospectively discontinued erythrocyte transfusions in a new and larger cohort of pediatric patients with SCD and stroke. We used daily oral HU therapy to help prevent stroke recurrence and an aggressive periodic phlebotomy regimen to reduce iron overload. Our preliminary results suggest that some children with SCD and stroke may be able to discontinue chronic transfusions and use daily oral HU therapy as stroke prophylaxis. Phlebotomy is well-tolerated and significantly reduces serum ferritin values.

Patient selection.

A total of 25 patients with SCD and stroke who were followed by the Duke University Pediatric Sickle Cell Program (Durham, NC) were considered for this protocol. Sixteen patients were identified who had clinical events or sequelae that suggested they would be unable to tolerate indefinite chronic erythrocyte transfusion therapy. Reasons to consider discontinuing transfusions included erythrocyte alloimmunization, erythrocyte autoantibody formation, recurrent stroke on transfusion therapy, iron overload (serum ferritin >2,000 ng/mL), and noncompliance with transfusion or chelation regimens. The remaining 9 patients were not offered enrollment, because they had received blood transfusions for less than 2 years or had no clinical or laboratory contraindications to continuing chronic transfusion therapy. The study protocol was approved by the Duke University Medical Center Institutional Review Board, and the consent form described the high risk of recurrent stroke once transfusions were stopped. In all cases, at least two different health care providers independently discussed the risks and benefits with each family before enrollment.

Discontinuation of transfusions and initiation of hydroxyurea therapy.

Before discontinuing transfusions, patients were screened for abnormal hepatic or renal function, and also for exposure to hepatitis A, B, and C, as well as the human immunodeficiency virus. Approximately 2 weeks after the last transfusion, at a time when endogenous erythropoiesis was recovering, oral HU therapy was started at a dose of 15 mg/kg/d. The dose of HU was escalated by 5 mg/kg/d every 8 weeks as tolerated, up to a maximum of 30 mg/kg/d. If a patient developed hematologic toxicity, defined as a hemoglobin concentration <5.0 g/dL, an absolute neutrophil count of <1.5 × 109/L, or a platelet count <80 × 109/L, HU therapy was held until blood counts normalized.

Phlebotomy regimen.

Patients with laboratory evidence of iron overload were started on a periodic phlebotomy program designed to remove excess iron and stimulate erythropoiesis. Phlebotomy was typically performed in the outpatient setting by the Duke pediatric hematology/oncology nursing staff. Five children also had phlebotomy periodically performed at home by trained pediatric nurses from a home health care agency. Using peripheral access, 5 to 10 mL/kg of venous blood was removed over 20 to 40 minutes and discarded. Vital signs were monitored every 10 minutes. Intravascular volume was replaced using an equivalent volume of normal saline given intravenously over 30 minutes. Phlebotomy was initially performed every 4 weeks, but an interval of 2 weeks was tolerated well by most patients.

Quantitation of HbF and F cells.

Measurement of HbF and F cells was performed every 8 weeks. The %HbF was determined using the 2-minute alkali denaturation procedure, and the %F cells using an immunophenotype assay as previously described.22 

Statistical analysis.

All clinical and laboratory data were maintained in a Microsoft Excel database (Redmond, WA). Descriptive statistics were calculated using the Primer of Biostatistics (McGraw-Hill, New York, NY). The Wilcoxon Signed Rank Test (Statview, SAS Institute, Cary, NC) was used to compare serum ferritin values before and after phlebotomy.23 

Characteristics of the patients.

Each of the 16 eligible patients (11 males, 5 females) chose to enroll in this study. Clinical characteristics are summarized in Table 1. Fifteen of the children have a diagnosis of homozygous sickle cell anemia (HbSS), whereas one child has a diagnosis of HbS/OArab. The mean age (±1 standard deviation [SD]) at first stroke was 7.1 ± 4.4 years, with a median of 6.4 years. In all cases, the initial stroke was infarctive, including 7 presenting with right hemiparesis (4 with concomitant aphasia), 4 with left hemiparesis, 4 with focal neurological deficitis, and 1 with coma and seizures.

Table 1.

Clinical Characteristics of 16 Pediatric Patients With SCD and Stroke Who Discontinued Chronic Transfusions and Received Oral Hydroxyurea Therapy to Prevent Stroke Recurrence

Patient No. Hemoglobin DiagnosisAge at First Stroke (yr) Type of StrokeTransfusions Reasons to Stop Transfusions Age Transfusions Stopped (yr)
moType
1  SS  12.3  R hemiplegia  82 S, E, P  AlloAb, AutoAb, Iron, NC  19.1  
2  SS  4.5 R exotropia  47  S, E, P  AutoAb, NC  8.4  
3  SS 5.7  L hemiplegia  7  S  AutoAb  6.3  
4  SS 7.7  R hemiplegia, aphasia  13  S  2nd stroke on transfusions  8.8  
5  SS  6.5  L hemiplegia  72 S, E, P  AlloAb, AutoAb  16.7  
6  SS  6.4  R hemiplegia, aphasia  72  S, E, P  Iron, NC  12.3  
SS  5.3  R hemiplegia, aphasia  37  S, E  Iron 8.4  
8  SS  5.5  Coma, seizures  127  S, E, P Iron, DFO allergy  16.1  
9  SS  6.5  R hemiplegia 79  S, P  Iron, NC  13.1  
10  SS  8.3  R hand 34  S, E  Iron, NC  11.2  
11  SS  17.3  L hemiplegia  28  S, E  NC  19.7  
12  SS  3.0  L hemiplegia  54  S  Iron, DFO allergy  7.6  
13  SS 15.0  R hemiplegia, aphasia  39  S, E  Iron, NC 18.4  
14  SOArab 1.1  L hand 22  S  Iron  2.9  
15  SS  6.3  R hemiplegia 54  S, E, P  Iron  10.7  
16  SS  2.7  L hand 127  S  Iron  13.3 
Patient No. Hemoglobin DiagnosisAge at First Stroke (yr) Type of StrokeTransfusions Reasons to Stop Transfusions Age Transfusions Stopped (yr)
moType
1  SS  12.3  R hemiplegia  82 S, E, P  AlloAb, AutoAb, Iron, NC  19.1  
2  SS  4.5 R exotropia  47  S, E, P  AutoAb, NC  8.4  
3  SS 5.7  L hemiplegia  7  S  AutoAb  6.3  
4  SS 7.7  R hemiplegia, aphasia  13  S  2nd stroke on transfusions  8.8  
5  SS  6.5  L hemiplegia  72 S, E, P  AlloAb, AutoAb  16.7  
6  SS  6.4  R hemiplegia, aphasia  72  S, E, P  Iron, NC  12.3  
SS  5.3  R hemiplegia, aphasia  37  S, E  Iron 8.4  
8  SS  5.5  Coma, seizures  127  S, E, P Iron, DFO allergy  16.1  
9  SS  6.5  R hemiplegia 79  S, P  Iron, NC  13.1  
10  SS  8.3  R hand 34  S, E  Iron, NC  11.2  
11  SS  17.3  L hemiplegia  28  S, E  NC  19.7  
12  SS  3.0  L hemiplegia  54  S  Iron, DFO allergy  7.6  
13  SS 15.0  R hemiplegia, aphasia  39  S, E  Iron, NC 18.4  
14  SOArab 1.1  L hand 22  S  Iron  2.9  
15  SS  6.3  R hemiplegia 54  S, E, P  Iron  10.7  
16  SS  2.7  L hand 127  S  Iron  13.3 

Abbreviations: R, right; L, left; S, simple transfusions; E, erythrocytapheresis; P, partial exchange transfusions; AlloAb, erythrocyte alloantibodies; AutoAb, erythrocyte autoantibodies; DFO, deferoxamine; NC, noncompliance; SS, homozygous sickle cell anemia; SOArab, heterozygous HbS and HbOArab.

Each patient had previously received erythrocyte tranfusions to prevent stroke recurrence, mean duration of 56 ± 36 months, median 51 months (Table 1). Fifteen children had received transfusions for at least 1 year; one (#3) discontinued transfusions after 7 months because of erythrocyte autoantibody and alloantibody formation. All 16 children had received blood via simple erythrocyte transfusions, but 7 also received partial exchange transfusions and 10 had erythrocytapheresis as previously described.24 One patient (#16) was seropositive to hepatitic C. Nine patients were prescribed deferoxamine (DFO) chelation therapy; 2 were compliant, 5 were noncompliant, and 2 were allergic. Patient #8 developed a generalized pruritic rash with periorbital edema; DFO desensitization was attempted, but was unsuccessful. Patient #12 had significant pain and swelling at the DFO infusion site with a maculopapular rash on the arms and chest; desensitization was not attempted.

The reasons to consider discontinuing transfusions varied among the 16 patients (Table 1). Four developed erythrocyte autoantibodies, as recently described.25 Two of these patients also developed multiple erythrocyte alloantibodies; patient #1 developed alloantibodies to the public Dib antigen and to a variant D antigen, whereas patient #5 developed alloantibodies to C, Jsa, and Lea antigens.25 Additional reasons to consider discontinuing transfusions included recurrent stroke while on transfusions (n = 1), iron overload (n = 11), and noncompliance with the transfusion regimen (n = 4) or chelation therapy (n = 5). At the time that transfusions were stopped, the patients had a mean age of 12.1 ± 4.9 years, median 11.8 years.

Hydroxyurea therapy.

The patients have received oral HU therapy for a mean duration of 22 ± 14 months, median 22 months (Table2). The current average HU dose is 24.9 ± 4.2 mg/kg/d, range 19.1 to 32.7 mg/kg/d. Hematologic toxicity has been mild, with only occasional episodes of transient, reversible myelosuppression (not shown).

Table 2.

Laboratory Parameters for 16 Pediatric Patients With SCD and Stroke Who Discontinued Chronic Transfusions and Began Oral HU Therapy to Prevent Stroke Recurrence

Patient No. HU Therapy (mo)HU Dose (mg/kg/d) Hb (g/dL) MCV (fL) HbF (%) F Cells (%)Phlebotomy Ferritin (ng/mL)
moTotal mL mL/kg Initial Latest
1  52  32.7 8.6  102  15.7  69.9  45  19,562  322  8,830 2,962  
2  38  19.9  8.6  122  28.1  90.3 35  15,030  405  2,628  419  
3  37  26.4 10.3  116  29.6  95.0  ND  ND ND  560  225  
4  36  29.9  10.5  107 31.2  95.8  19  7,412  282  2,153  90  
33  20.1  10.5  114  27.9  89.0  14  4,460 90  1,025  169  
6  27  19.1  10.1  116 20.6  85.0  27  17,090  326  5,950  1,911  
23  28.1  9.0  100  11.9  58.7  20  8,765 308  2,631  235  
8  22  27.0  10.0  129 23.6  88.5  23  19,825  306  4,206  1,326  
21  27.8  8.0  123  18.3  78.8  21  9,590 261  7,281  3,161  
10  20  21.8  8.8  104 27.8  90.0  17  12,695  272  2,877  128  
11 16  20.1  11.9  112  22.7  86.3  ND ND  ND  267  188  
12  14  25.3 10.6  122  29.2  95.9  14  9,220  233  2,012 424  
13  3  23.8  7.5  107  13.3  69.5  3,000  48  2,486  1,309  
14  10  30.0  9.5 104  11.2  55.0  10  3,610  194  2,081  319 
15  4  22.2  7.4  108  8.2  63.4  4  1,835 58  1,808  1,297  
16  3  24.5  8.8  105 9.6  57.5  3  2,450  60  2,700 ND 
Patient No. HU Therapy (mo)HU Dose (mg/kg/d) Hb (g/dL) MCV (fL) HbF (%) F Cells (%)Phlebotomy Ferritin (ng/mL)
moTotal mL mL/kg Initial Latest
1  52  32.7 8.6  102  15.7  69.9  45  19,562  322  8,830 2,962  
2  38  19.9  8.6  122  28.1  90.3 35  15,030  405  2,628  419  
3  37  26.4 10.3  116  29.6  95.0  ND  ND ND  560  225  
4  36  29.9  10.5  107 31.2  95.8  19  7,412  282  2,153  90  
33  20.1  10.5  114  27.9  89.0  14  4,460 90  1,025  169  
6  27  19.1  10.1  116 20.6  85.0  27  17,090  326  5,950  1,911  
23  28.1  9.0  100  11.9  58.7  20  8,765 308  2,631  235  
8  22  27.0  10.0  129 23.6  88.5  23  19,825  306  4,206  1,326  
21  27.8  8.0  123  18.3  78.8  21  9,590 261  7,281  3,161  
10  20  21.8  8.8  104 27.8  90.0  17  12,695  272  2,877  128  
11 16  20.1  11.9  112  22.7  86.3  ND ND  ND  267  188  
12  14  25.3 10.6  122  29.2  95.9  14  9,220  233  2,012 424  
13  3  23.8  7.5  107  13.3  69.5  3,000  48  2,486  1,309  
14  10  30.0  9.5 104  11.2  55.0  10  3,610  194  2,081  319 
15  4  22.2  7.4  108  8.2  63.4  4  1,835 58  1,808  1,297  
16  3  24.5  8.8  105 9.6  57.5  3  2,450  60  2,700 ND 

The %HbF and %F cells refer to the maximal values during HU therapy. The initial ferritin refers to the time that transfusions were discontinued.

Abbreviations: Hb, recent hemoglobin concentration; MCV, recent mean corpuscular volume; ND, not done.

Representative data illustrating the hematologic effects of HU therapy are shown in Table 2. Recent laboratory values include a mean hemoglobin concentration of 9.4 ± 1.3 g/dL (median 9.3 g/dL) and a mean corpuscular volume (MCV) of 112 ± 9 fL (median 110 fL). Using the maximal laboratory values for each patient during HU therapy, the mean %HbF is 20.6% ± 8.0% (median 21.7%), whereas the mean %F cells is 79.3% ± 14.7% (median 85.7%).

Phlebotomy regimen.

Fourteen of the children had laboratory evidence of iron overload and have received phlebotomy for a mean duration of 18 ± 12 months, median 18 months (Table 2). The total volume of blood removed has ranged from 1,835 to 19,825 mL, with a median volume of 8,993 mL. When calculated in milliliters of blood removed per kilogram of body weight, the phlebotomy volume has ranged from 48 to 405 mL/kg, with a median volume of 267 mL/kg (Table 2).

Serum ferritin values before and after phlebotomy are also shown in Table 2. The 14 children who received phlebotomy had an initial median ferritin value of 2,630 ng/mL, and their most recent median ferritin value has fallen to 424 ng/mL. Seven of the 14 phlebotomized patients currently have a serum ferritin value under 500 ng/mL (Table 2). A comparison of initial and latest serum ferritin values shows a significant diminution in response to phlebotomy, P = 0.0015 by Wilcoxon Signed Rank Test.

Clinical events.

No patient developed acute chest syndrome or other non-neurological vaso-occlusive events requiring transfusions while on HU therapy. Six children (38%) had minor painful events requiring outpatient analgesia; patients #1 and #6 were hospitalized once for management of pain. Three patients had new neurological events consistent with recurrent stroke. Patient #13 had a severe occipital headache 13 weeks after discontinuing transfusion therapy. Magnetic resonance imaging (MRI) showed a new occipital infarction, and monthly transfusion therapy was restarted. Patient #15 developed right hemiparesis 16 weeks after discontinuing transfusion therapy, and MRI showed a recurrent left cortical infarction. Her symptoms resolved after double-volume exchange transfusion, and she resumed monthly erythrocytapheresis. Patient #16 had isolated left-hand weakness 11 weeks after starting HU therapy; brain MRI was normal, but diffusion studies were consistent with a new left cortical infarct. His symptoms quickly resolved after exchange transfusion, and he also resumed monthly transfusions. No patient has experienced a hemorrhagic neurological event while on HU therapy.

Our results provide the first preliminary data to suggest that hydroxyurea may be effective in the clinical setting of cerebrovascular disease in patients with SCD. The 16 pediatric patients with stroke who enrolled in this protocol discontinued transfusions prospectively after receiving blood for an average of almost 5 years, presumably with a substantial (≈50%) risk of stroke recurrence.20 The reasons to discontinue blood transfusions varied among our patients (Table 1) and included an inability to find compatible blood because of severe erythrocyte alloimmunization or autoantibody formation,24 recurrent stroke while on transfusions, noncompliance with the transfusion or chelation regimen, and severe iron overload with DFO allergy. Several of our patients had a very high risk for recurrence, including one child (#4) who had a second stroke while on transfusions and 2 others (#3, #14) who had received transfusions for less than 24 months (Table 1). With a median follow-up of 22 months, our patients had a stroke recurrence rate of only 19%, suggesting that HU therapy may have helped to prevent recurrent stroke. In comparison, the stroke recurrence rate at our institution for patients receiving chronic transfusion therapy is approximately 11%, similar to that recently reported by Pegelow and colleagues.18 

The mechanisms by which HU might provide protection against stroke recurrence are not known, but the increase in HbF parameters (%HbF and %F cells) likely is important in the prevention of in vivo sickling within the stenotic cerebral vessels. Our patients achieved an average %HbF of approximately 20% and %F cells of approximately 80% (Table2), values that should inhibit intracellular sickling.26Additional possible mechanisms include reductions in total white blood cell count and absolute neutrophil count that accompany HU therapy,27-29 as well as improved rheological characteristics of the erythrocytes caused by changes in erythrocyte morphology, adhesiveness, and cation content.30,31 

Each of the recurrent neurological events occurred approximately 3 to 4 months after discontinuing transfusion therapy. This is likely the period of highest risk for stroke recurrence, during which endogenous HbS-containing erythrocytes are replacing the transfused erythrocytes, but before the maximal beneficial hematologic effects of HU therapy. The recently completed pediatric HU safety trial (HUG-KIDS), using the same HU dose escalation schedule, showed that the hemoglobin concentration, MCV, %HbF, and %F cells increase during the first 6 months of HU therapy, but continue to increase between 6 and 12 months of therapy.29 At the time of their stroke recurrence, our 3 children had an average %HbF level of only 10.4%, well below the %HbF levels achieved by the other patients after prolonged HU therapy. More rapid escalation of the HU dose, or initiating HU therapy several months before discontinuing transfusions, might lead to a more rapid rise in HbF parameters and help prevent these cases of early stroke recurrence. Importantly, no patient experienced a hemorrhagic neurological event as was previously described in a 20-year-old male with cerebrovascular disease receiving HU therapy.32 

The phlebotomy program was designed to reduce the iron burden and stimulate erythropoiesis, thereby increasing the number of HbF-containing reticulocytes and preventing stroke recurrence. The phlebotomy regimen has been very well tolerated, and most patients have 10 mL/kg blood removed every 2 weeks while maintaining a hemoglobin concentration above 8 g/dL (Table 2). Phlebotomy has led to steady reductions in the total body iron stores, with substantial diminution in the serum ferritin of all 14 patients who received phlebotomy. Seven of the 14 patients who received phlebotomy currently have a serum ferritin <500 ng/mL, and phlebotomy has been discontinued in 4 children whose ferritin values decreased to approximately 200 ng/mL. These results compare favorably with those reported for patients with beta-thalassemia, who received phlebotomy after curative allogeneic bone marrow transplantation and had eventual mobilization of tissue iron and reduction in liver iron concentration.33 Although we have not performed a quantitative liver biopsy for iron burden on our patients, one had superconducting susceptometry (SQUID) analysis performed after stopping phlebotomy and was found to have normal hepatic iron stores. SQUID analysis or liver biopsy may be necessary in selected patients to confirm normalization of hepatic iron.

HU has been shown to be effective in reducing the number of painful events, transfusions, and episodes of acute chest syndrome in adults with sickle cell anemia.34 Similar clinical benefits have been reported in small groups of pediatric patients.35-39Based on our encouraging preliminary single-institution results, we believe that larger multicenter trials may be warranted to determine the clinical efficacy of HU in pediatric patients with sickle cell disease, especially in the setting of cerebrovascular disease. To test formally the efficacy of HU in preventing recurrent stroke, children could receive prophylactic erythrocyte transfusions for 2 to 3 years after the initial event, then randomize to either (1) continued transfusions with iron chelation or (2) HU and phlebotomy to alleviate iron overload. The study end points should include not only recurrent clinical neurological events and changes in brain MR imaging and angiography, but also financial costs, quality of life, and the possible sequelae of continued transfusion therapy such as transmission of infection, erythrocyte allosensitization, and iron overload. Improved testing of blood units for infectious pathogens and the use of antigen matching has reduced much of the morbidity associated with chronic erythrocyte transfusion therapy, but iron overload remains a serious long-term problem.40 Finally, HU could also be considered for the prevention of primary stroke. Adams et al41 have recently shown that transcranial doppler (TCD) can identify children with SCD who have an increased risk of primary stroke, and that transfusion therapy can prevent primary stroke in this clinical setting.42 As additional children with SCD and elevated TCD values become identified, perhaps HU therapy should be considered as an alternative to chronic transfusions in this asymptomatic population of patients.

The authors thank Dr Thomas R. Kinney and Erin O’Branski for support of this clinical protocol and Dr Gary Brittenham for SQUID analysis. The authors are also grateful to the nurses in the Duke Pediatric Hematology/Oncology out-patient clinic, especially Jayne Cash, Anne Fitzgerald, and Karen Lewis, and to the nurses at Pediatric Services of America; without their dedication, the phlebotomy regimen could not have been successfully completed.

Supported in part by the Duke Children’s Miracle Network Telethon.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

1
Leikin
SL
Gallagher
D
Kinney
TR
Sloane
D
Klug
P
Rida
W
Mortality in children and adolescents with sickle cell disease.
Pediatrics
84
1989
500
2
Gray
A
Anionwu
EN
Davies
SC
Brozovic
M
Patterns of mortality in sickle cell disease in the United Kingdom.
J Clin Pathol
44
1991
459
3
Serjeant
GR
The clinical features of sickle cell disease.
Baillieres Clin Haematol
6
1993
93
4
Balkaran
B
Char
G
Morris
JS
Thomas
PW
Serjeant
BE
Serjeant
GR
Stroke in a cohort of patients with homozygous sickle cell disease.
J Pediatr
120
1992
360
5
Ohene-Frempong
K
Weiner
SJ
Sleeper
LA
Miller
ST
Embury
S
Moohr
JW
Wethers
DL
Pegelow
CH
Gill
FM
Cerebrovascular accidents in sickle cell disease: Rates and risk factors.
Blood
91
1998
288
6
Stockman
JA
Nigro
MA
Mishkin
MM
Oski
FA
Occlusion of large cerebral vessels in sickle-cell anemia.
N Engl J Med
287
1972
846
7
Adams
RJ
Nichols
FT
McKie
V
McKie
K
Milner
P
Gammal
TE
Cerebral infarction in sickle cell anemia: Mechanism based on CT and MRI.
Neurology
38
1988
1012
8
Ohene-Frempong
K
Stroke in sickle cell disease: Demographic, clinical and therapeutic considerations.
Semin Hematol
28
1991
213
9
Craft
S
Schatz
J
Glauser
TA
Lee
B
DeBaun
MR
Neuropsychologic effects of stroke in children with sickle cell anemia.
J Pediatr
123
1993
712
10
Cohen
MJ
Branch
WB
McKie
VC
Adams
RJ
Neuropsychological impairment in children with sickle cell anemia and cerebrovascular accidents.
Clin Pediatr
33
1994
517
11
Powars
D
Wilson
B
Imbus
C
Pegelow
C
Allen
J
The natural history of stroke in sickle cell disease.
Am J Med
65
1978
461
12
Russell
MO
Goldberg
HI
Hodson
A
Kim
HC
Halos
J
Reivich
M
Schwartz
E
Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease.
Blood
63
1984
162
13
Milner
PF
Chronic transfusion regimens in sickle cell disease.
Prog Clin Biol Res
98
1982
97
14
Piomelli
S
Chronic transfusions in patients with sickle cell disease.
Am J Pediatr Hematol/Oncol
7
1985
51
15
Lusher
JM
Haghighat
H
Khalifa
AS
A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction.
Am J Hematol
1
1976
265
16
Russell
MO
Goldberg
HI
Reis
L
Friedman
S
Slater
R
Reivich
M
Schwartz
E
Transfusion therapy for cerebrovascular abnormalities in sickle cell disease.
J Pediatr
88
1976
382
17
Sarnaik
S
Soorya
D
Kim
J
Ravindranath
Y
Lusher
J
Periodic transfusions for sickle cell anemia and CNS infarction.
Am J Dis Child
133
1979
1254
18
Peglow
CH
Adams
RJ
McKie
V
Abboud
M
Berman
B
Miller
ST
Olivieri
N
Vichinsky
E
Wang
W
Brambilla
D
Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions.
J Pediatr
126
1995
896
19
Wilimas
J
Goff
JR
Anderson
HR
Jr
Langston
JW
Thompson
E
Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents.
J Pediatr
96
1980
205
20
Wang
WC
Kovnar
EH
Tonkin
IL
Mulhern
RK
Langston
JW
Day
SW
Schell
MJ
Wilimas
JA
High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease.
J Pediatr
118
1991
377
21
Ware
RE
Steinberg
MH
Kinney
TR
Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia.
Am J Hematol
50
1995
140
22
Marcus
SJ
Kinney
TR
Schultz
WH
O’Branski
EE
Ware
RE
Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease.
Am J Hematol
54
1997
40
23
Hollander
M
Wolfe
D
Nonparametric Statistical Methods.
1973
Wiley
New York, NY
24
Adams
DM
Schultz
WH
Ware
RE
Kinney
TR
Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients.
Am J Pediatr Hematol/Oncol
18
1996
46
25
Castellino
SM
Combs
MR
Zimmerman
SA
Issitt
PD
Ware
RE
Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: Frequency, characteristics, and significance.
Br J Haematol
104
1999
189
26
Noguchi
CT
Rodgers
GP
Serjeant
GR
Schechter
AN
Levels of fetal hemoglobin necessary for treatment of sickle cell disease.
N Engl J Med
318
1988
96
27
Platt
OS
Orkin
SH
Dover
G
Beardsley
GP
Miller
B
Nathan
DG
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
J Clin Invest
74
1984
652
28
Charache
S
Dover
GJ
Moore
RD
Eckert
S
Ballas
SK
Koshy
M
Milner
PF
Orringer
EP
Phillips
G
Jr
Platt
OS
Thomas
GH
Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia.
Blood
79
1992
2555
29
Kinney TR, Helms RW, O’Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE: Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a Phase I/II trial. Blood, in press
30
Adragna
NC
Fonseca
P
Lauf
PK
Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells.
Blood
83
1994
553
31
Bridges
KR
Barabino
GD
Brugnara
C
Cho
MR
Christoph
GW
Dover
G
Ewenstein
BM
Golan
DE
Guttmann
CR
Hofrichter
J
Mulkern
RV
Zhang
B
Eaton
WA
A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy.
Blood
88
1996
4701
32
Vichinsky
EP
Lubin
BH
A cautionary note regarding hydroxyurea in sickle cell disease.
Blood
83
1994
1124
33
Angelucci
E
Muretto
P
Lucarelli
G
Ripalti
M
Baronciani
D
Erer
B
Galimberti
M
Giardini
C
Gazier
D
Polchi
P
Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation.
Blood
90
1997
994
34
Charache
S
Terrin
ML
Moore
RD
Dover
GJ
Barton
FB
Eckert
SV
McMahon
RP
Bonds
DR
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia.
N Engl J Med
332
1995
1317
35
Scott
JP
Hillery
CA
Brown
ER
Misiewicz
V
Labotka
RJ
Hydroxyurea therapy in children severely affected with sickle cell disease.
J Pediatr
128
1996
820
36
Jayabose
S
Tugal
O
Sandoval
C
Patel
P
Puder
D
Lin
T
Visintainer
P
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
J Pediatr
129
1996
559
37
Ferster
A
Vermylen
C
Cornu
G
Buyse
M
Corazza
F
Devalck
C
Fondu
P
Toppet
M
Sariban
E
Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial.
Blood
88
1996
1960
38
de Montalembert
M
Belloy
M
Bernaudin
F
Gouraud
F
Capdeville
R
Mardini
R
Philippe
N
Jais
JP
Bardakdjian
J
Ducrocq
R
Maier-Redelsperger
M
Elion
J
Labie
D
Girot
R
Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
J Pediatr Hematol Oncol
19
1997
313
39
Olivieri
NF
Vichinsky
EP
Hydroxyurea in children with sickle cell disease: Impact on splenic function and compliance with therapy.
J Pediatr Hematol Oncol
20
1998
26
40
Rosse
WF
Telen
MJ
Ware
RE
Transfusion support for patients with sickle cell disease.
1998
AABB Press
Bethesda, MD
41
Adams
R
McKie
V
Nichols
F
Carl
E
Zhang
DL
McKie
K
Figueroa
R
Litaker
M
Thompson
W
Hess
D
The use of transcranial ultrasonography to predict stroke in sickle cell disease.
N Engl J Med
326
1992
605
42
Adams
RJ
McKie
VC
Hsu
L
Files
B
Vichinsky
E
Pegelow
C
Abboud
M
Gallagher
D
Kutlar
A
Nichols
FT
Bonds
DR
Brambilla
D
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.
N Engl J Med
339
1998
5

Patient 11, who was originally noncompliant with transfusions, became noncompliant with hydroxyurea after 17 months and refused further therapy. Four months later he developed a recurrent left hemiplegia.

Author notes

Address reprint requests to Russell E. Ware, MD, PhD, PO Box 2916, Duke University Medical Center, Durham, NC 27710; e-mail:ware0005@mc.duke.edu.